JP4606048B2 - ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 - Google Patents
ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 Download PDFInfo
- Publication number
- JP4606048B2 JP4606048B2 JP2004087529A JP2004087529A JP4606048B2 JP 4606048 B2 JP4606048 B2 JP 4606048B2 JP 2004087529 A JP2004087529 A JP 2004087529A JP 2004087529 A JP2004087529 A JP 2004087529A JP 4606048 B2 JP4606048 B2 JP 4606048B2
- Authority
- JP
- Japan
- Prior art keywords
- mrsa
- yamabushitake
- agent
- present
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims description 28
- 229960003085 meticillin Drugs 0.000 title claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 title claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 6
- 206010041925 Staphylococcal infections Diseases 0.000 description 43
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 43
- 239000003795 chemical substances by application Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000000605 extraction Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 235000013305 food Nutrition 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000134916 Amanita Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DMNLGXJDSXLETO-UHFFFAOYSA-N CC1OC(CC(CO)(O)OC2)C12O Chemical compound CC1OC(CC(CO)(O)OC2)C12O DMNLGXJDSXLETO-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 241000959662 Hydnaceae Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000014537 nerve growth factor production Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
項1. 下記一般式(1)で表される化合物。
項3. 酢酸エチル、エタノール、メタノール、アセトン及びこれらと水の混合物よりなる群から選択される少なくとも1種の溶媒を用いてヤマブシタケの子実体を抽出することにより得られる抽出物を有効成分とする、抗メチシリン耐性黄色ブドウ球菌剤。
(1)分子量:190.0841(C8H14O5)
(2)色及び形状:無色アモルファス
(3)溶媒に対する溶解性:(酢酸エチル、メタノール、エタノール、アセトン)に可溶;水にやや可溶
(4)塩基性、中性、酸性の別:(中性)
(5)核磁気共鳴スペクトル(1H−NMR):1.30 (d, J=6.4), 1.88 (d, J=14.3), 2.45 (dd, J=14.3, 9.8), 3.33 (b, s), 3.82 (q, J=6.4), 3.74 (d, J=8.1), 3.89 (J=9.8), 4.06 (d, J=8.1)
(6)核磁気共鳴スペクトル(13CNMR):15.1, 39.7, 61.9, 66.5, 69.5, 70.5, 75.3, 97.6
当該一般式(1)で表される化合物は、MRSAに対して優れた抗菌作用を発揮できるので、抗MRSA剤の有効成分として用いることができる。また、前述するように、ヤマブシタケの上記溶媒抽出物には一般式(1)で表される化合物が含有されており、当該抽出物を抗MRSA剤の有効成分として用いることもできる。
ヤマブシタケの乾燥子実体3.8kgをクロロホルム20Lに加えて、ホモジナイズ処理し25℃で12時間、静置した。次いで、固形分を回収し、該固形分(乾燥重量)3.7kgを酢酸エチル20Lに加えて、25℃で12時間、静置した。
MRSA2932株(臨床分離菌、名古屋大学医学部から入手)を5mLの液体培地を用いて、30℃で16時間、200rpmで振とう培養し、MRSA培養液を得た。このMRSA培養液を20倍に希釈したもの100μLをトリプトソーヤ寒天培地プレート(表面積60.8cm2、TSA培地、Becton Dickinson社製)に塗抹し、これを検定用培地とした。該検定用培地に、実施例1で得られた一般式(1)で表される化合物を1mg/mLの濃度で含有する水溶液を染み込ませて乾燥させたペーパーディスク(抗生物質検定用8mm、アドバンテック社製)を、静かにピンセットで乗せて、30℃で20時間培養を行った。培養後、検定用培地に生成した阻止円の直径を測定し、下記式に従って抗菌活性を求めた。
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004087529A JP4606048B2 (ja) | 2004-03-24 | 2004-03-24 | ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004087529A JP4606048B2 (ja) | 2004-03-24 | 2004-03-24 | ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005272346A JP2005272346A (ja) | 2005-10-06 |
JP4606048B2 true JP4606048B2 (ja) | 2011-01-05 |
Family
ID=35172389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004087529A Expired - Lifetime JP4606048B2 (ja) | 2004-03-24 | 2004-03-24 | ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4606048B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5088911B2 (ja) * | 2011-03-02 | 2012-12-05 | 国立大学法人北海道大学 | 抗微生物物質産生・分泌促進剤 |
WO2013011679A1 (ja) * | 2011-07-15 | 2013-01-24 | 株式会社王樹製薬 | 抗菌剤とその製造方法 |
KR101815113B1 (ko) * | 2015-12-01 | 2018-01-05 | 이대희 | 노루궁뎅이버섯 추출물 및 코디세핀을 이용한 껌 조성물 및 그 제조 방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06116162A (ja) * | 1992-10-06 | 1994-04-26 | Toyo Seiyaku Kk | ブドウ球菌抗菌剤 |
JPH06256378A (ja) * | 1993-03-04 | 1994-09-13 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH06256352A (ja) * | 1993-03-04 | 1994-09-13 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH0770168A (ja) * | 1993-08-31 | 1995-03-14 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH0770133A (ja) * | 1993-08-31 | 1995-03-14 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH10120589A (ja) * | 1996-10-21 | 1998-05-12 | Kazuo Sakuma | 抗菌剤及び抗菌性食品 |
JP2005239669A (ja) * | 2004-02-27 | 2005-09-08 | Yukito Akiyama | シアタン誘導体及びこれを有効成分とする抗菌剤 |
-
2004
- 2004-03-24 JP JP2004087529A patent/JP4606048B2/ja not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06116162A (ja) * | 1992-10-06 | 1994-04-26 | Toyo Seiyaku Kk | ブドウ球菌抗菌剤 |
JPH06256378A (ja) * | 1993-03-04 | 1994-09-13 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH06256352A (ja) * | 1993-03-04 | 1994-09-13 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH0770168A (ja) * | 1993-08-31 | 1995-03-14 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH0770133A (ja) * | 1993-08-31 | 1995-03-14 | Kagome Co Ltd | シアタン誘導体及びこれを有効成分とする神経成長因子産生誘導剤並びに抗菌剤 |
JPH10120589A (ja) * | 1996-10-21 | 1998-05-12 | Kazuo Sakuma | 抗菌剤及び抗菌性食品 |
JP2005239669A (ja) * | 2004-02-27 | 2005-09-08 | Yukito Akiyama | シアタン誘導体及びこれを有効成分とする抗菌剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2005272346A (ja) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ndip et al. | In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon | |
EP2826473B1 (en) | Antibacterial use of patchoulol | |
CN101128114B (zh) | 18元环大环化合物及其类似物 | |
CN101102761B (zh) | 木酚素类化合物用于治疗或预防炎症性疾病的用途 | |
Padhi et al. | Antibacterial activity of Eleutherine bulbosa against multidrug-resistant bacteria | |
TW200800140A (en) | Antimicrobial agent and antimicrobial composition | |
Bensizerara et al. | Antimicrobial activity of xerophytic plant (Cotula cinerea Delile) extracts against some pathogenic bacteria and fungi | |
CN102743741A (zh) | 蟑螂多肽的制备及其抗革兰氏阳性及阴性菌医药用途 | |
Evaristo et al. | Antimicrobial effect of the triterpene 3β, 6β, 16β-trihydroxylup-20 (29)-ene on planktonic cells and biofilms from Gram positive and Gram negative bacteria | |
CN103341114A (zh) | 草果油在制备治疗细菌感染性疾病的药物中的用途 | |
WO2014019485A1 (zh) | 广藿香酮的新用途 | |
CN102058660B (zh) | 藿香油在制备治疗细菌感染性疾病的药物中的用途 | |
JP4606048B2 (ja) | ヤマブシタケに含まれる新規化合物及び抗メチシリン耐性黄色ブドウ球菌剤 | |
KR101574003B1 (ko) | 전나무 잎 정유를 함유하는, 호흡기질환 관련 박테리아에 대한 항균 조성물 | |
Shushizadeh et al. | Preparation of the Persian Gulf Echinometra mathaei Organic Extracts and Investigation of Their Antibacterial Activity | |
JP2005023000A (ja) | 抗菌剤及びその製造方法、並びに食品製剤及び消毒剤 | |
KR101106056B1 (ko) | 병원성미생물에 대하여 항균활성을 나타내는 식물 또는 그 추출물을 유효성분으로 하는 항생용 조성물 | |
Bbosa et al. | The activity of Mangifera indica L. leaf extracts against the tetanus causing bacterium, Clostridium tetani | |
Lee et al. | Color alteration and acaricidal activity of juglone isolated from Caesalpinia sappan heartwoods against Dermatophagoides spp. | |
CN106867674A (zh) | 一种豆腐菜挥发油的提取纯化和检测方法及其应用 | |
Jagessar et al. | Leaf extract of Smilax schomburgkiana exhibit selective antimicrobial properties against pathogenic microorganisms | |
CN108003099B (zh) | 一种双苄基四氢异喹啉类化合物及其制备方法和应用 | |
Akbarizare | GC-MS Analysis and Antimicrobial Activity of an Iranian Traditional Medicinal Smoke (Anbarnasara) | |
JP4061675B2 (ja) | 天然物由来の抗菌剤 | |
Airaodion et al. | Investigation of antibacterial activity of Vernonia amygdalina leaf extracts against gram-positive and gram-negative bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100824 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20100824 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100914 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4606048 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |